What Happens to Your Sample When a Pharmacy Sends It for Testing

When a compounding pharmacy claims its products are "independently tested," what does that actually involve? The phrase sounds reassuring, but the value depends entirely on what's being tested, by whom, and how the results are used. This article follows a compounded semaglutide sample from the pharmacy's shelf to the testing laboratory's report — step by step.

Step 1: Sample Selection

Testing begins with deciding what to test. Quality-focused pharmacies sample from finished product batches rather than just raw API. This distinction matters because finished product testing captures errors introduced during the compounding process itself — incorrect weighing, dilution mistakes, contamination during filling — that API testing alone would miss.

The pharmacy selects representative vials from a compounded batch. For statistical validity, multiple vials from the same batch may be sent — testing a single vial confirms that vial's quality but says less about batch consistency. The sample vials are labeled with the batch number, compounding date, formulation details, and the tests requested.

Step 2: Chain of Custody

The samples are shipped to the testing laboratory under conditions that maintain product integrity — typically cold-chain shipping for injectable preparations. A chain-of-custody document accompanies the samples, recording who collected them, when, and how they were stored and transported. This documentation ensures the laboratory is testing the actual product, not a degraded or substituted sample.

Reputable testing laboratories maintain incoming sample logs and verify the condition of received samples before beginning analysis. If samples arrive warm, damaged, or without proper documentation, the laboratory should flag the issue before proceeding.

Step 3: Identity Confirmation

The laboratory's first task is confirming the sample contains what the label says it contains. For compounded semaglutide, identity testing typically involves HPLC analysis comparing the sample's chromatographic profile against a certified semaglutide reference standard. If the sample's retention time and peak characteristics match the reference, identity is confirmed.

This step catches the most serious quality failure: a vial that contains the wrong drug entirely. While this scenario is uncommon in licensed pharmacies, it has been documented in FDA enforcement cases involving unlicensed sellers and gray market products.

Step 4: Potency Assay

The quantitative heart of the testing: how much semaglutide is actually in the solution? The laboratory performs a quantitative HPLC assay, measuring the concentration of semaglutide against calibration standards of known concentration. The result is reported as a percentage of the labeled claim — ideally between 90% and 110%.

A result of 95% means the vial contains 95% of the semaglutide stated on the label. At standard clinical doses, this 5% deficit is within the pharmacological margin and unlikely to affect clinical response. A result of 75% means the patient is receiving substantially less drug than prescribed — a clinically significant underdose.

Step 5: Impurity Profiling

The HPLC analysis that measures potency also reveals impurity peaks — chromatographic signals from compounds other than semaglutide present in the sample. The laboratory quantifies each impurity peak as a percentage of the total and compares against established specification limits.

For pharmaceutical peptides, typical specifications require individual impurities below 1.0% and total impurities below 3-5%. Impurities above these thresholds may indicate API degradation, contamination, or poor-quality starting material.

Step 6: Sterility Testing

For injectable preparations, sterility testing (USP <71>) determines whether the product is free of viable microorganisms. The laboratory transfers a portion of the sample into two types of growth media — one designed to support bacterial growth and one for fungal growth — and incubates them for 14 days at appropriate temperatures.

If no microbial growth is detected after 14 days, the sample passes. If growth is detected, the test is repeated to rule out laboratory contamination. A confirmed positive sterility test means the batch is contaminated and should not be used.

Step 7: Endotoxin Testing

Bacterial endotoxin testing (USP <85>) uses the Limulus Amebocyte Lysate (LAL) assay to detect pyrogens — bacterial membrane fragments that can cause fever and inflammatory reactions when injected. Unlike sterility testing, LAL testing provides results within hours, making it practical for batch-release decisions.

The result is reported in Endotoxin Units per milliliter (EU/mL). Injectable products must fall below the calculated endotoxin limit, which depends on the dose and route of administration.

Step 8: Report Issuance

The laboratory compiles all test results into a certificate of analysis (CoA) that reports each test performed, the method used, the specification (acceptance criteria), and the actual result. The CoA is signed by an authorized laboratory representative and returned to the pharmacy.

A complete CoA for a compounded semaglutide injectable should include: identity confirmation, potency assay, impurity profile, sterility test result, endotoxin test result, pH measurement, visual inspection results, and the beyond-use date assigned to the batch.

Step 9: What the Pharmacy Does With the Results

This is where pharmacy quality systems diverge most significantly:

• Pass — release: If all results meet specifications, the batch is approved for dispensing.
• Fail — quarantine and investigate: If any result falls outside specifications, the batch should be quarantined and an investigation initiated. Depending on the failure type, the pharmacy may retest, reject the batch, or — in the worst case — issue a recall if the batch was already dispensed.
• Trending: Quality-focused pharmacies don't just look at pass/fail — they trend results over time. A potency result that's been drifting downward batch after batch (98%... 96%... 93%) may still pass specifications but signals a developing problem that needs investigation before a failure occurs.

Providers That Invest in Independent Testing